David S. Janowsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David S. Janowsky has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
John M. Davis
From the *Department of Psychiatry, University of North Carolina Chapel Hill, Chapel Hill; †Murdoch Center, Butner, NC; and ‡Department of Psychiatry, University of Illinois, Chicago, IL
12 shared publicationsL. Jarrett Barnhill
4 shared publicationsQiaoyan Hu
From the *Department of Psychiatry, University of North Carolina Chapel Hill, Chapel Hill; †Murdoch Center, Butner, NC; and ‡Department of Psychiatry, University of Illinois, Chicago, IL
3 shared publicationsAbdul S. Khalid
2 shared publicationsBelal Elamir
2 shared publicationsDavid H. Overstreet
Department of Psychiatry, CB# 7175, Medical Research Building A, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7175, USA
2 shared publications
Latest Publications
- 1 December 2011
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 31 (6) , 769-773
Lithium-Induced Renal Insufficiency
Background: Lithium has been shown to increase serum creatinine levels in a subgroup of patients. However, lithium-induced increases in serum creatinine have not been well studied with regard to timing, trajectory, or predictability. Methods: The medical records of 16 intellectually disabled individuals treated with lithium between 1980 and 2010 in whom serum creatinine levels peaked at 1.5 mg/100 mL or higher (ie, who developed renal insufficiency) were reviewed. These individuals were compared with a group of 36 similar lithium-treated individuals in whom serum creatinine did not reach 1.5 mg/100 mL. Results: The 16 lithium-treated individuals who developed renal insufficiency had a mean peak serum creatinine level of 1.8 ± 0.3 mg/100 mL while on lithium. The mean time from institution of lithium until the 1.5 mg/100 mL serum creatinine level was first reached was 7.9 years. After lithium was discontinued, overall mean serum creatinine levels did not significantly change. Reaching a serum creatinine level of 1.3 or 1.4 mg/100 mL predicted reaching a 1.5 mg/100 mL level or higher. No significant differences in the age lithium was started, baseline serum creatinine levels, years receiving lithium, sex, or race differentiated those who developed renal insufficiency. Conclusions: Prescribing lithium led to elevated serum creatinine levels in some individuals. A serum creatinine level of 1.3 and/or 1.4 mg/100 mL predicted renal insufficiency. Clinical implications of this study are that if 1 serum creatinine result reaches 1.3 mg/100 mL or more, intensive monitoring for further increases is indicated.
- 1 December 2011
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 31 (6) , 769-773
Lithium-Induced Renal Insufficiency
Background: Lithium has been shown to increase serum creatinine levels in a subgroup of patients. However, lithium-induced increases in serum creatinine have not been well studied with regard to timing, trajectory, or predictability. Methods: The medical records of 16 intellectually disabled individuals treated with lithium between 1980 and 2010 in whom serum creatinine levels peaked at 1.5 mg/100 mL or higher (ie, who developed renal insufficiency) were reviewed. These individuals were compared with a group of 36 similar lithium-treated individuals in whom serum creatinine did not reach 1.5 mg/100 mL. Results: The 16 lithium-treated individuals who developed renal insufficiency had a mean peak serum creatinine level of 1.8 ± 0.3 mg/100 mL while on lithium. The mean time from institution of lithium until the 1.5 mg/100 mL serum creatinine level was first reached was 7.9 years. After lithium was discontinued, overall mean serum creatinine levels did not significantly change. Reaching a serum creatinine level of 1.3 or 1.4 mg/100 mL predicted reaching a 1.5 mg/100 mL level or higher. No significant differences in the age lithium was started, baseline serum creatinine levels, years receiving lithium, sex, or race differentiated those who developed renal insufficiency. Conclusions: Prescribing lithium led to elevated serum creatinine levels in some individuals. A serum creatinine level of 1.3 and/or 1.4 mg/100 mL predicted renal insufficiency. Clinical implications of this study are that if 1 serum creatinine result reaches 1.3 mg/100 mL or more, intensive monitoring for further increases is indicated.
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 31 (2) , 238-240
Minimum Effective and Relapse-Associated Doses of Risperidone and Olanzapine in Aggressive, Intellectually Disabled Adults
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 31 (2) , 238-240
Minimum Effective and Relapse-Associated Doses of Risperidone and Olanzapine in Aggressive, Intellectually Disabled Adults
- 29 November 2009
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 11 (6) , 509-511
Bipolar disorder- and major depression-relevant abstracts from the 2009 9th World Congress of Biological Psychiatry Meeting
The author has reviewed selected bipolar disorder- and major depression-relevant abstracts from the 2009 9th World Congress of Biological Psychiatry Meeting in Paris. The seven selected abstracts, which represent a small percentage of the presentations made at the meeting, explore the relationship between bipolar and unipolar diagnoses and suicidal behavior, the differentiation of bipolar I and bipolar II disorder, and some novel non-industry-supported treatments of bipolar and unipolar depression.
- 29 November 2009
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 11 (6) , 509-511
Bipolar disorder- and major depression-relevant abstracts from the 2009 9th World Congress of Biological Psychiatry Meeting
The author has reviewed selected bipolar disorder- and major depression-relevant abstracts from the 2009 9th World Congress of Biological Psychiatry Meeting in Paris. The seven selected abstracts, which represent a small percentage of the presentations made at the meeting, explore the relationship between bipolar and unipolar diagnoses and suicidal behavior, the differentiation of bipolar I and bipolar II disorder, and some novel non-industry-supported treatments of bipolar and unipolar depression.
- 1 June 2009
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 29 (3) , 296-299
Lithium Effect on Renal Glomerular Functionin Individuals With Intellectual Disability
Objective: The current study evaluated the effects of chronic administration of lithium on renal functioning in an intellectually disabled population. Methods: Fifty-seven lithium-treated individuals were compared with 24 behaviorally symptomatic controls using a retrospective chart review method. Serum creatinine levels and creatinine clearance activities were compared at baseline, at the time of peak creatinine levels, and at the end of the study in 2006. Results: The mean length of lithium administration was 8.76 years (range, 1-23 years). Chronic lithium administration yielded a significant increase in peak serum creatinine levels and a decrease in the corresponding creatinine clearance activity. Of the subjects, 22.8% had peak creatinine levels of 1.5 mg or higher per 100 mL (a common threshold for renal insufficiency). This contrasted with 0% (none) for the symptomatic control subjects (P = 0.008). In addition, 26.3% of the lithium-treated subjects had creatinine clearance activities less than 55 mL/min and 17.5% had less than 50 mL/min, both indicative of renal insufficiency, versus none of the symptomatic control subjects (P = 0.004 and P = 0.029, respectively). With lithium withdrawal, further deterioration of renal function did not occur in most cases, and many showed improvement, with decreases in serum creatinine levels and increases in creatinine clearance activity. Conclusions: Chronic administration of lithium led to clinically significant increases in serum creatinine levels and decreases in creatinine clearance in lithium-treated intellectually disabled individuals.
- 1 June 2009
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 29 (3) , 296-299
Lithium Effect on Renal Glomerular Functionin Individuals With Intellectual Disability
Objective: The current study evaluated the effects of chronic administration of lithium on renal functioning in an intellectually disabled population. Methods: Fifty-seven lithium-treated individuals were compared with 24 behaviorally symptomatic controls using a retrospective chart review method. Serum creatinine levels and creatinine clearance activities were compared at baseline, at the time of peak creatinine levels, and at the end of the study in 2006. Results: The mean length of lithium administration was 8.76 years (range, 1-23 years). Chronic lithium administration yielded a significant increase in peak serum creatinine levels and a decrease in the corresponding creatinine clearance activity. Of the subjects, 22.8% had peak creatinine levels of 1.5 mg or higher per 100 mL (a common threshold for renal insufficiency). This contrasted with 0% (none) for the symptomatic control subjects (P = 0.008). In addition, 26.3% of the lithium-treated subjects had creatinine clearance activities less than 55 mL/min and 17.5% had less than 50 mL/min, both indicative of renal insufficiency, versus none of the symptomatic control subjects (P = 0.004 and P = 0.029, respectively). With lithium withdrawal, further deterioration of renal function did not occur in most cases, and many showed improvement, with decreases in serum creatinine levels and increases in creatinine clearance activity. Conclusions: Chronic administration of lithium led to clinically significant increases in serum creatinine levels and decreases in creatinine clearance in lithium-treated intellectually disabled individuals.
- 1 December 2008
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 10 (6) , 525-527
Bipolar disorder-relevant abstracts of posters from the 2008 CINP congress
The author has reviewed bipolar disorder-relevant abstracts from the July 2008 Munich CINP (Collegium Internationale Neuro-Psychopharmacologicum) meeting. Seven abstracts are summarized, focusing on the psychopharmacologic treatment of bipolar depression, the neuropsychological effects of psychotropic drugs used to treat bipolar disorder, and the relationship of mood stabilizers and antidepressants to emotional instability over time.
- 1 December 2008
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 10 (6) , 525-527
Bipolar disorder-relevant abstracts of posters from the 2008 CINP congress
The author has reviewed bipolar disorder-relevant abstracts from the July 2008 Munich CINP (Collegium Internationale Neuro-Psychopharmacologicum) meeting. Seven abstracts are summarized, focusing on the psychopharmacologic treatment of bipolar depression, the neuropsychological effects of psychotropic drugs used to treat bipolar disorder, and the relationship of mood stabilizers and antidepressants to emotional instability over time.
- 1 August 2008
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 28 (4) , 401-405
Antipsychotic Withdrawal-Induced Relapse Predicts Future Relapses in Institutionalized Adults With Severe Intellectual Disability
Severe intellectual and developmental disabilities are frequently associated with aggression toward self and others, destruction of property, and disruption. Antipsychotic medications are a mainstay of treatment of such behaviors. National and state guidelines suggest stopping these medications or decreasing their dosages when possible if patients have maintained stability. The current study evaluated the likelihood of future antipsychotic drug withdrawal-induced relapses in those individuals where such a relapse had occurred previously. Subjects were 57 institutionalized adults with severe or profound intellectual disability. Between 1990 and 2000, each had experienced an initial activation of maladaptive aggressive behaviors after an attempt at antipsychotic drug withdrawal and/or termination. Quarterly behavioral reports were evaluated to determine whether subsequent antipsychotic drug withdrawal attempts were also associated with future relapses. Initial relapse was followed by subsequent antipsychotic drug withdrawal attempts in 49 of the 57 individuals. Between 1990 and 2005, 28.6% of these 49 subjects had experienced 1, 38.7% had 2, 20.4% had 3, and 8.2% had 4 additional relapses. Two (4.1%) had not relapsed. Eight individuals remained on antipsychotic agents without a subsequent withdrawal attempt. By the end of 2005, only 4 (7%) of the 57 individuals had become antipsychotic drug free, 22.8% were receiving first-generation antipsychotic agents alone, 45.6% were receiving second-generation antipsychotic agents alone, and 24.6% were receiving a combination of first- and second-generation antipsychotic agents. Thus, if relapse occurs after an antipsychotic drug withdrawal attempt, subsequent attempts at withdrawal are also very likely to lead to further relapses.
- 1 August 2008
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 28 (4) , 401-405
Antipsychotic Withdrawal-Induced Relapse Predicts Future Relapses in Institutionalized Adults With Severe Intellectual Disability
Severe intellectual and developmental disabilities are frequently associated with aggression toward self and others, destruction of property, and disruption. Antipsychotic medications are a mainstay of treatment of such behaviors. National and state guidelines suggest stopping these medications or decreasing their dosages when possible if patients have maintained stability. The current study evaluated the likelihood of future antipsychotic drug withdrawal-induced relapses in those individuals where such a relapse had occurred previously. Subjects were 57 institutionalized adults with severe or profound intellectual disability. Between 1990 and 2000, each had experienced an initial activation of maladaptive aggressive behaviors after an attempt at antipsychotic drug withdrawal and/or termination. Quarterly behavioral reports were evaluated to determine whether subsequent antipsychotic drug withdrawal attempts were also associated with future relapses. Initial relapse was followed by subsequent antipsychotic drug withdrawal attempts in 49 of the 57 individuals. Between 1990 and 2005, 28.6% of these 49 subjects had experienced 1, 38.7% had 2, 20.4% had 3, and 8.2% had 4 additional relapses. Two (4.1%) had not relapsed. Eight individuals remained on antipsychotic agents without a subsequent withdrawal attempt. By the end of 2005, only 4 (7%) of the 57 individuals had become antipsychotic drug free, 22.8% were receiving first-generation antipsychotic agents alone, 45.6% were receiving second-generation antipsychotic agents alone, and 24.6% were receiving a combination of first- and second-generation antipsychotic agents. Thus, if relapse occurs after an antipsychotic drug withdrawal attempt, subsequent attempts at withdrawal are also very likely to lead to further relapses.
- 1 November 2006
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 8 (6) , 470-472
Recent depression updates: Relevant presentations
This review discusses several depression-relevant abstracts of posters and talks presented at the 2005 American College of Neuropsychopharmacology Annual Meeting and the 2006 Collegium Internationale Neuro-Psychopharmacologicum Meeting. Described are several novel psychopharmacologic treatments for major depressive disorder, some predictors of efficacy, and information relevant to understanding the activation of the hypothalamicpituitary-adrenal axis in depression.
- 1 November 2006
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 8 (6) , 470-472
Recent depression updates: Relevant presentations
This review discusses several depression-relevant abstracts of posters and talks presented at the 2005 American College of Neuropsychopharmacology Annual Meeting and the 2006 Collegium Internationale Neuro-Psychopharmacologicum Meeting. Described are several novel psychopharmacologic treatments for major depressive disorder, some predictors of efficacy, and information relevant to understanding the activation of the hypothalamicpituitary-adrenal axis in depression.
- 15 August 2006
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 67 (08) , 1272-1277
Relapse of Aggressive and Disruptive Behavior in Mentally Retarded Adults Following Antipsychotic Drug Withdrawal Predicts Psychotropic Drug Use a Decade Later
Mental retardation is frequently associated with aggression toward self and others. Antipsychotic medications are frequently used as a major treatment of such aggression. However, national and state policies and guidelines are weighted toward stopping or decreasing the doses of these medications whenever possible, although exceptions are permitted. The purpose of this study was to determine if relapse during or after antipsychotic drug withdrawal in mentally retarded adults predicts continuing antipsychotic drug use an average of a decade later. We report here on a 6- to 13-year (average 10-year) follow-up of 151 institutionalized mentally retarded adults. During the period 1990-1997, the subjects had been prescribed antipsychotic medications to treat maladaptive behaviors, primarily consisting of aggression, disruptive/destructive behaviors, or a combination of these. We compared subjects' psychotropic medication profiles in 2003 as they related to outcome during the earlier period. Our goal was to determine if rapid relapse (a clinically significant increase in maladaptive target symptoms, beginning 3 months or less after antipsychotic drug termination or dosage reduction, that was reversed by antipsychotic drug reinstitution or dosage increases) during or after routine withdrawal of an antipsychotic predicted psychotropic drug use in 2003. For those individuals successfully withdrawn from antipsychotic medications, 66.3% (55/83) were still psychotropic drug free in 2003. For those who rapidly relapsed during the period 1990-1997 following antipsychotic drug withdrawal or dosage decreases, only 9.0% (5/55) were psychotropic medication free in 2003. These observations support policies and guidelines indicating that attempts to stop treatment with antipsychotic medications in mentally retarded individuals are worthwhile. However, the results also indicate that eventual discontinuation of antipsychotic medications in institutionalized mentally retarded adults who have previously relapsed upon such withdrawal is unlikely to be successful. Rigid adherence to drug withdrawal policies and guidelines in such individuals should be reconsidered.
- 15 August 2006
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 67 (08) , 1272-1277
Relapse of Aggressive and Disruptive Behavior in Mentally Retarded Adults Following Antipsychotic Drug Withdrawal Predicts Psychotropic Drug Use a Decade Later
Mental retardation is frequently associated with aggression toward self and others. Antipsychotic medications are frequently used as a major treatment of such aggression. However, national and state policies and guidelines are weighted toward stopping or decreasing the doses of these medications whenever possible, although exceptions are permitted. The purpose of this study was to determine if relapse during or after antipsychotic drug withdrawal in mentally retarded adults predicts continuing antipsychotic drug use an average of a decade later. We report here on a 6- to 13-year (average 10-year) follow-up of 151 institutionalized mentally retarded adults. During the period 1990-1997, the subjects had been prescribed antipsychotic medications to treat maladaptive behaviors, primarily consisting of aggression, disruptive/destructive behaviors, or a combination of these. We compared subjects' psychotropic medication profiles in 2003 as they related to outcome during the earlier period. Our goal was to determine if rapid relapse (a clinically significant increase in maladaptive target symptoms, beginning 3 months or less after antipsychotic drug termination or dosage reduction, that was reversed by antipsychotic drug reinstitution or dosage increases) during or after routine withdrawal of an antipsychotic predicted psychotropic drug use in 2003. For those individuals successfully withdrawn from antipsychotic medications, 66.3% (55/83) were still psychotropic drug free in 2003. For those who rapidly relapsed during the period 1990-1997 following antipsychotic drug withdrawal or dosage decreases, only 9.0% (5/55) were psychotropic medication free in 2003. These observations support policies and guidelines indicating that attempts to stop treatment with antipsychotic medications in mentally retarded individuals are worthwhile. However, the results also indicate that eventual discontinuation of antipsychotic medications in institutionalized mentally retarded adults who have previously relapsed upon such withdrawal is unlikely to be successful. Rigid adherence to drug withdrawal policies and guidelines in such individuals should be reconsidered.
- 1 December 2005
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 7 (6) , 485-486
Current issues in the treatment of depression in bipolar disorder patients
Reviewing abstracts of posters and presentations at scientific meetings offers a rapid overview summary of the state of the art of a given discipline and/or disorder, with data presented being available months to years before formal publication occurs. This article reviews selected abstracts of posters presented at the Sixth International Conference on Bipolar Disorder, held in Pittsburgh, PA June 16–18, 2005. The review consists of the consideration of nine published abstracts (of a total of 278 abstracts). The major focus of this review is on the nature and treatment of depression in bipolar disorder patients, and includes information generally not previously circulated to psychiatric professionals.
- 1 December 2005
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 7 (6) , 485-486
Current issues in the treatment of depression in bipolar disorder patients
Reviewing abstracts of posters and presentations at scientific meetings offers a rapid overview summary of the state of the art of a given discipline and/or disorder, with data presented being available months to years before formal publication occurs. This article reviews selected abstracts of posters presented at the Sixth International Conference on Bipolar Disorder, held in Pittsburgh, PA June 16–18, 2005. The review consists of the consideration of nine published abstracts (of a total of 278 abstracts). The major focus of this review is on the nature and treatment of depression in bipolar disorder patients, and includes information generally not previously circulated to psychiatric professionals.
- 1 August 2005
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 81 (4) , 917-922
Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: A potential nerve agent treatment
- 1 August 2005
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 81 (4) , 917-922
Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: A potential nerve agent treatment